Drug intelligence / Profile preview

RD1104

Development stage: Preclinical
Lead developer: Pharmgen Science
Modality: Small Molecules

Overview

RD1104 is a small molecule therapeutic candidate being developed by Pharmgen Science for the treatment of blood coagulation disorders. It is categorized within the company's post-patent pipeline, which typically includes generic drugs or incrementally modified drugs (IMDs) targeting markets where original patents have expired. The drug is currently in the development stage, focusing on indications related to thrombosis and the prevention of blood clots. As a post-patent asset, it is designed to provide a more accessible or improved therapeutic option compared to existing anticoagulants.

Beyond the preview

Go deeper on RD1104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RD1104.

Explore the full profile